ORIGINAL ARTICLE
Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma – a retrospective study of 1433 cases from a single center
1
People’s Hospital of Xinjiang Uygur Autonomous Region
Submission date: 2021-07-28
Final revision date: 2022-06-22
Acceptance date: 2022-10-27
Publication date: 2023-01-10
Corresponding author
Yaoyuan Shen
Yaoyuan Shen, People’s Hospital of Xinjiang Uygur Autonomous Region Xinjiang, China
Yaoyuan Shen, People’s Hospital of Xinjiang Uygur Autonomous Region Xinjiang, China
Pol J Pathol 2022;73(3):191-197
KEYWORDS
TOPICS
ABSTRACT
The purpose of this retrospective study was to evaluate the clinicopathological features of papillary thyroid microcarcinoma (PTMC) and the lymph node metastasis of PTMC.
We retrospectively reviewed a total of 1433 patients with PTMC. The analysis data including demographics, tumor size, multifocality, bilateral, invasion capsule and Hashimoto’s thyroiditis were collected from XinJiang, China.
Univariate and multivariate analyses were performed to identify the clinicopathologic predictors of central lymph node metastasis: male gender [odds ratio (OR) = 2.358, p < 0.001], age ≤ 45 years (OR = 2.302, p < 0.001), sum of tumor size > 6.5 mm (OR = 2.388, p < 0.001), adjacent or invasion capsule (OR = 1.750, p = 0.002), Hashimoto’s thyroiditis (OR = 0.501, p < 0.001). The optimal critical value of the number of dissected lymph nodes was found to be 8.5 using ROC analysis, with a sensitivity and specificity of 41.8% and 75.5%, respectively.
This study suggests that evaluation of nodal metastasis is required to guide the surgical treatment of PTMC patients.
We retrospectively reviewed a total of 1433 patients with PTMC. The analysis data including demographics, tumor size, multifocality, bilateral, invasion capsule and Hashimoto’s thyroiditis were collected from XinJiang, China.
Univariate and multivariate analyses were performed to identify the clinicopathologic predictors of central lymph node metastasis: male gender [odds ratio (OR) = 2.358, p < 0.001], age ≤ 45 years (OR = 2.302, p < 0.001), sum of tumor size > 6.5 mm (OR = 2.388, p < 0.001), adjacent or invasion capsule (OR = 1.750, p = 0.002), Hashimoto’s thyroiditis (OR = 0.501, p < 0.001). The optimal critical value of the number of dissected lymph nodes was found to be 8.5 using ROC analysis, with a sensitivity and specificity of 41.8% and 75.5%, respectively.
This study suggests that evaluation of nodal metastasis is required to guide the surgical treatment of PTMC patients.
REFERENCES (39)
1.
Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014; 99: E276-E285.
2.
Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw 2014; 12: 1671-1680.
3.
Du L, Wang Y, Sun X, et al. Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China[J]. BMC Cancer, 2018,18(1):291.
4.
Dal Maso L, Panato C, Franceschi S, et al. The impact of overdiagnosis on thyroid cancer epidemic in Italy,1998–2012[J]. Eur J Cancer 2018; 94: 6-15.
5.
Kakudo K. Asian and Western practice in thyroid pathology: similarities and differences. Gland Surg 2020; 9: 1614-1627.
6.
Gao M, Ge M, Ji Q, et al. Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer Biol Med 2017; 14: 203-211.
7.
Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg 2015; 4: 52-62.
8.
Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer. Endocr J 2020; 67: 669-717.
9.
Lee J, Song Y, Soh EY. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma. J Korean Med Sci 2014; 29: 48-52.
10.
Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope 2011; 121: 487-491.
11.
Liu LS, Liang J, Li JH, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 2017; 274: 1327-1338.
12.
Song J, Yan T, Qiu W, et al. Clinical analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study of 3686 patients. Cancer Manag Res 2020; 12: 2523-2530.
13.
Wang Y, Guan Q, Xiang J. Nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study of 8668 patients. Int J Surg 2018; 55: 98-102.
14.
Wang ZH, Zhang YJ, Fu GM, et al. [Analysis of risk factors for central lymph node metastasis in papillary thyroid microcarcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2019; 54: 12-17.
15.
Feng JW, Pan H, Wang L, et al. Determine the optimal extent of thyroidectomy and lymphadenectomy for patients with papillary thyroid microcarcinoma. Front Endocrinol (Lausanne) 2019; 10: 363.
16.
Xu Y, Xu L, Wang J. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res 2018; 221: 128-134.
17.
Jeon MJ, Kim WG, Choi YM, et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 2016; 26: 161-168.
18.
Luo Y, Zhao Y, Chen K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest 2019; 42: 227-236.
19.
Yin X, Liu C, Guo Y, et al. Influence of tumor extent on central lymph node metastasis in solitary papillary thyroid microcarcinomas: a retrospective study of 1092 patients. World J Surg Oncol 2017; 15: 133.
20.
Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 2006; 30: 91-99.
21.
Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol 2010; 6: 1771-1779.
22.
Gui CY, Qiu SL, Peng ZH, et al. Clinical and pathologic predictors of central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study. J Endocrinol Invest 2018; 41: 403-409.
23.
Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: a retrospective study. World J Surg Oncol 2012; 10: 67.
24.
Turk AT, Asa SL, Baloch ZW, et al. Interobserver variability in the histopathologic assessment of extrathyroidal extension of well differentiated thyroid carcinoma supports the New American Joint Committee on cancer eighth edition criteria for tumor staging. Thyroid 2019; 29: 619-624.
25.
Tran B, Roshan D, Abraham E, et al. An analysis of the American Joint Committee on cancer 8th edition T staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab 2018; 103: 2199-2206.
26.
Yin DT, Yu K, Lu RQ, et al. Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma. Medicine (Baltimore) 2016; 95: e5794.
27.
Diker-Cohen T, Hirsch D, Shimon I, et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 2018.
28.
Song J, Yan T, Qiu W, et al. Clinical analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study of 3686 patients[J]. Cancer Manag Res 2020; 12: 2523-2530.
29.
Wang W, Gu J, Shang J, et al. Correlation analysis on central lymph node metastasis in 276 patients with cN0 papillary thyroid carcinoma. Int J Clin Exp Pathol 2013; 6: 510-515.
30.
Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr Relat Cancer 2016; 23: 27-34.
31.
Lang BH, Chai YJ, Cowling BJ, et al. Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma? Endocr Relat Cancer 2014; 21: 285-295.
32.
Kim SS, Lee BJ, Lee JC, et al. Preoperative ultrasonographic tumor characteristics as a predictive factor of tumor stage in papillary thyroid carcinoma. Head Neck 2011; 33: 1719-1726.
33.
Wen X, Wang B, Jin Q, et al. Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with hashimoto’s thyroiditis. Ann Surg Oncol 2019; 26: 1751-1758.
34.
Shen CT, Zhang XY, Qiu ZL, et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine 2017; 58: 176-183.
35.
Iliadou PK, Effraimidis G, Konstantinos M, et al. Chronic lymphocytic thyroiditis is associated with invasive characteristics of differentiated thyroid carcinoma in children and adolescents. Eur J Endocrinol 2016; 174: X1.
36.
Sun L, Li P, Ren H, et al. Quantifying the number of lymph nodes for examination in breast cancer. J Int Med Res 2020; 48: 1219679146.
37.
Sun L, Liu Q, Ren H, et al. Nodes staging score to quantify lymph nodes for examination in gastric cancer. Medicine (Baltimore) 2020; 99: e21085.
38.
Ma D, Zhao S, Huang Y, et al. STARD: how many lymph nodals needed to be dissected in corpus carcinoma? Medicine (Baltimore) 2018; 97: e260.
39.
Robinson TJ, Thomas S, Dinan MA, et al. How many lymph nodes are enough? Assessing the adequacy of lymph node yield for papillary thyroid cancer. J Clin Oncol 2016; 34: 3434-3439.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
